Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBupa Fin. 35 Regulatory News (82GS)

Share Price Information for Bupa Fin. 35 (82GS)

Share Price is delayed by 15 minutes
Get Live Data
84.44    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: -
82GS Live PriceLast checked at - London Stock Exchange

Intraday Bupa Fin. 35 Share Chart

Prospectus published re EUR 500m Notes due 2030

10 Oct 2023 16:17

RNS Number : 6786P
BUPA Finance PLC
10 October 2023

Bupa Finance plcLEI Code: ZIMCVQHUFZ8GVHENP290

Bupa Finance plc publishes prospectus in relation to its offering of EUR 500 million Fixed Rate Notes due 12 October 2030

10 October 2023

Bupa Finance plc today announces that it has published a prospectus in relation to its EUR 500 million 5.00 per cent. fixed rate notes due 12 October 2030 (the "Senior Notes").

The prospectus has been approved by the Financial Conduct Authority and is now available for viewing. To view the full document, please click here:

http://www.rns-pdf.londonstockexchange.com/rns/6786P_1-2023-10-10.pdf

The prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The Senior Notes will be issued by Bupa Finance plc on 12 October 2023. The Senior Notes are guaranteed by The British United Provident Association Limited ("Bupa").

For further information, please contact:

Investors

Investor Relations: ir@bupa.com

Media

External Relations: external.relations@bupa.com

DISCLAIMER

This announcement is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy the Senior Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.

Please note that the information contained in the prospectus may be addressed to and/or targeted at persons who are residents of particular countries only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offers contained in the prospectus are not addressed. Prior to relying on the information contained in the prospectus, you must ascertain from the prospectus whether or not you are one of the intended addressees of the information contained therein.

The Senior Notes will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any U.S. state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Senior Notes will be only offered and sold to non-U.S. persons in offshore transactions outside the United States in accordance with Regulation S under the Securities Act.

Stabilisation in respect of the Senior Notes may be conducted in accordance with FCA and International Capital Market Association Rules.

About Bupa

Bupa's purpose is helping people live longer, healthier and happier lives and making a better world. We are an international healthcare company serving over 43 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers.

We directly employ around 82,000 people, principally in the UK, Australia, Spain, Chile, Poland, New Zealand, Hong Kong, SAR, TΓΌrkiye, Brazil, Mexico, the US, Middle East and Ireland. We also have associate businesses in Saudi Arabia and India.

For more information, visit www.bupa.com.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
PDIFFDFISEDSEFS
Date   Source Headline
20th May 20261:17 pmRNSMoody's Affirms Bupa's Rating
5th Mar 20267:00 amRNSAnnual Financial Report
20th Nov 20254:33 pmRNSDebt Issuance & Tender Offer - Final Announcement
18th Nov 20251:35 pmRNSTender Offer - Final Results
18th Nov 20259:25 amRNSTender Offer - Indicative Results
14th Nov 20254:34 pmRNSIssuance - Publication of Admission Particulars
12th Nov 202510:19 amRNSTender Offer - Maximum Acceptance Amount
10th Nov 20258:42 amRNSTender Offer
7th Aug 20257:00 amRNSHalf-year Report
6th Mar 20257:00 amRNSAnnual Financial Report
15th Oct 20246:00 pmRNSFitch Ratings upgrades Bupa Finance plc
1st Aug 20247:00 amRNSHalf-year Report
10th Jul 202412:06 pmRNSMoody’s affirms Bupa Insurance Limited’s Rating
7th Mar 20247:00 amRNS2023 Annual Report
10th Nov 20239:00 amRNSPost Stabilisation Notice
10th Oct 20234:17 pmRNSProspectus published re EUR 500m Notes due 2030
5th Oct 20235:35 pmRNSPricing of EUR 500 million Fixed Rate Notes 2030
3rd Aug 20237:04 amRNSBupa Finance Plc Announces 2023 Half Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.